An Open-Label, Multicenter Study Evaluating the Long-Term Safety and Efficacy of SR121463B in Patients With Syndrome of Inappropriate Antidiuretic Hormone Secretion
Latest Information Update: 03 Oct 2021
Price :
$35 *
At a glance
- Drugs Satavaptan (Primary)
- Indications Hyponatraemia; Inappropriate antidiuretic hormone secretion
- Focus Adverse reactions; Registrational
- Acronyms SIADH Safety
- Sponsors Sanofi
- 13 May 2014 New trial record
- 26 Nov 2007
- 13 Jun 2006